99 related articles for article (PubMed ID: 8379045)
1. [Risk for developing tumors in therapy with the proton pump inhibitor omeprazole].
Eissele R; Arnold R
Versicherungsmedizin; 1993 Aug; 45(4):126-9. PubMed ID: 8379045
[TBL] [Abstract][Full Text] [Related]
2. [What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Arnold R
Fortschr Med; 1994 Jan; 112(1-2):44-5. PubMed ID: 8144120
[No Abstract] [Full Text] [Related]
3. Omeprazole.
Med Lett Drugs Ther; 1990 Mar; 32(813):19-21. PubMed ID: 2179694
[No Abstract] [Full Text] [Related]
4. [Comment on the contribution: "Effect of omeprazole on serum gastrin levels: influence of age and sex" by Koop et al].
Miederer SE
Z Gastroenterol; 1991 Apr; 29(4):177-8. PubMed ID: 1866976
[No Abstract] [Full Text] [Related]
5. Omeprazole: long-term safety.
Arnold R; Koop H
Digestion; 1989; 44 Suppl 1():77-86. PubMed ID: 2691313
[TBL] [Abstract][Full Text] [Related]
6. Serum gastrin levels during long-term omeprazole treatment.
Koop H; Klein M; Arnold R
Aliment Pharmacol Ther; 1990 Apr; 4(2):131-8. PubMed ID: 2104080
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility and safety of omeprazole.
Walan A
Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279
[TBL] [Abstract][Full Text] [Related]
8. [Omeprazole in the therapy of acid-induced diseases].
Simon B; Dammann HG; Müller P
Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
[TBL] [Abstract][Full Text] [Related]
9. The clinical safety of omeprazole.
Sölvell L
Scand J Gastroenterol Suppl; 1989; 166():106-10; discussion 111-3. PubMed ID: 2690327
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with omeprazole: assessment of efficacy and safety.
Walan A
J Gastroenterol Hepatol; 1989; 4 Suppl 2():27-33. PubMed ID: 2491359
[TBL] [Abstract][Full Text] [Related]
11. [Omeprazole. A new substance for inhibiting acid production].
Uhl D
Med Monatsschr Pharm; 1990 Feb; 13(2):34-7. PubMed ID: 2179691
[No Abstract] [Full Text] [Related]
12. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
13. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
Jensen RT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
[TBL] [Abstract][Full Text] [Related]
14. [Anti-H2 and omeprazole in brief therapy of peptic ulcer].
Piai G; Sabbatini F; Mazzacca G
Ann Ital Chir; 1990; 61(1):11-4. PubMed ID: 1978622
[No Abstract] [Full Text] [Related]
15. Effect of omeprazole on serum gastrin levels: influence of age and sex.
Koop H; Naumann-Koch C; Arnold R
Z Gastroenterol; 1990 Nov; 28(11):603-5. PubMed ID: 1981116
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole, hypergastrinemia, and gastric carcinoid tumors.
Freston JW
Ann Intern Med; 1994 Aug; 121(3):232-3. PubMed ID: 8017751
[No Abstract] [Full Text] [Related]
17. Effect of enprostil on serum gastrin and pepsinogen A and C levels in patients on long-term treatment with omeprazole.
Meijer JL; Jansen JB; Biemond I; Kuijpers IJ; Lamers CB
Aliment Pharmacol Ther; 1994 Apr; 8(2):221-7. PubMed ID: 8038355
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic achlorhydria: for which diseases, when and for how long?].
Koop H; Arnold R
Dtsch Med Wochenschr; 1988 Mar; 113(13):516-8. PubMed ID: 2894969
[No Abstract] [Full Text] [Related]
19. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
20. Omeprazole: a new drug for the treatment of acid-peptic diseases.
Falk GW
Cleve Clin J Med; 1991; 58(5):418-27. PubMed ID: 1934456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
